{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:18Z","timestamp":1789753398747,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In Thailand, the incidence of community-acquired pseudomonal pneumonia among 60- to 65-year-olds ranges from 10.90% to 15.51%, with a mortality rate of up to 19.00%. Antipseudomonal agents should be selected as an empirical treatment for elderly patients at high risk for developing this infection. The purpose of this study was to identify risk factors and develop a risk predictor for <jats:italic>Pseudomonas aeruginosa<\/jats:italic> infection in older adults with community-acquired pneumonia (CAP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective data collection from an electronic database involved the elderly hospitalized patients with <jats:italic>P. aeruginosa<\/jats:italic>- and non-<jats:italic>P. aeruginosa<\/jats:italic>-causing CAP, admitted between January 1, 2016, and June 30, 2021. Risk factors for <jats:italic>P. aeruginosa<\/jats:italic> infection were analysed using logistic regression, and the instrument was developed by scoring each risk factor based on the beta coefficient and evaluating discrimination and calibration using the area under the receiver operating characteristic curve (AuROC) and observed versus predicted probability (E\/O) ratio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The inclusion criteria were met by 81 and 104 elderly patients diagnosed with CAP caused by <jats:italic>P. aeruginosa<\/jats:italic> and non-<jats:italic>P. aeruginosa<\/jats:italic>, respectively. Nasogastric (NG) tube feeding (odd ratios; OR\u2009=\u200940.68), bronchiectasis (B) (OR\u2009=\u20094.13), immunocompromised condition (I) (OR\u2009=\u20093.76), and other chronic respiratory illnesses (r) such as atelectasis, pulmonary fibrosis, and lung bleb (OR\u2009=\u20092.61) were the specific risk factors for infection with <jats:italic>P. aeruginosa<\/jats:italic>. The \u201c60-B-r-I-NG\u201d risk score was named after the 4 abbreviated risk variables and found to have good predicative capability (AuROC\u2009=\u20090.77) and accuracy comparable to or near true <jats:italic>P. aeruginosa<\/jats:italic> infection (E\/O\u2009=\u20091). People who scored at least two should receive empirically antipseudomonal medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NG tube feeding before admission, bronchiectasis, immunocompromisation, atelectasis, pulmonary fibrosis and lung bleb were risk factors for pseudomonal CAP in the elderly. The 60-B-r-I-NG was developed for predicting <jats:italic>P. aeruginosa<\/jats:italic> infection with a high degree of accuracy, equal to or comparable to the existing <jats:italic>P. aeruginosa<\/jats:italic> infection. Antipseudomonal agents may be started in patients who are at least 60\u00a0years old and have a score of at least 2 in order to lower mortality and promote the appropriate use of these medications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08688-w","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:02:39Z","timestamp":1697688159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-7457","authenticated-orcid":false,"given":"Kingkarn","family":"Wijit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8356-1265","authenticated-orcid":false,"given":"Paveena","family":"Sonthisombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-0897","authenticated-orcid":false,"given":"Jaruwan","family":"Diewsurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"issue":"7","key":"8688_CR1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8688_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.idc.2017.07.015","volume":"31","author":"O Henig","year":"2017","unstructured":"Henig O, Kaye KS. Bacterial pneumonia in older adults. Infect Dis Clin North Am. 2017;31(4):689\u2013713.","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"8688_CR3","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.4269\/ajtmh.20-1393","volume":"104","author":"M Osman","year":"2021","unstructured":"Osman M, Manosuthi W, Kaewkungwal J, Silachamroon U, Mansanguan C, Kamolratanakul S, et al. Etiology, clinical course, and outcomes of pneumonia in the elderly: a retrospective and prospective cohort study in Thailand. Am J Trop Med Hyg. 2021;104(6):2009\u201316.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"8688_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.chest.2016.03.042","volume":"150","author":"C Cill\u00f3niz","year":"2016","unstructured":"Cill\u00f3niz C, Gabarr\u00fas A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest. 2016;150(2):415\u201325.","journal-title":"Chest"},{"issue":"8","key":"8688_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/resp.12851","volume":"21","author":"JM Sahuquillo-Arce","year":"2016","unstructured":"Sahuquillo-Arce JM, Men\u00e9ndez R, M\u00e9ndez R, Amara-Elori I, Zalacain R, Capelastegui A, et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology. 2016;21(8):1472\u20139.","journal-title":"Respirology"},{"issue":"2","key":"8688_CR6","doi-asserted-by":"publisher","first-page":"1701190","DOI":"10.1183\/13993003.01190-2017","volume":"52","author":"MI Restrepo","year":"2018","unstructured":"Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52(2):1701190.","journal-title":"Eur Respir J"},{"issue":"1","key":"8688_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1060028020935106","volume":"55","author":"PO Lewis","year":"2021","unstructured":"Lewis PO. Risk factor evaluation for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in community-acquired pneumonia. Ann Pharmacother. 2021;55(1):36\u201343.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"8688_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1183\/09031936.00091809","volume":"35","author":"H von Baum","year":"2010","unstructured":"von Baum H, Welte T, Marre R, Suttorp N, Ewig S. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35(3):598\u2013605.","journal-title":"Eur Respir J"},{"issue":"9","key":"8688_CR9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/cid\/ciy723","volume":"68","author":"MF Di Pasquale","year":"2019","unstructured":"Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68(9):1482\u201393.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"8688_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","volume":"23","author":"LM Sullivan","year":"2004","unstructured":"Sullivan LM, Massaro JM, D\u2019Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med. 2004;23(10):1631\u201360.","journal-title":"Stat Med"},{"issue":"1","key":"8688_CR11","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1\u201373.","journal-title":"Ann Intern Med"},{"issue":"5","key":"8688_CR12","first-page":"237","volume":"11","author":"LA Mandell","year":"2000","unstructured":"Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000;11(5):237\u201348.","journal-title":"Can J Infect Dis"},{"issue":"10","key":"8688_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.arbres.2010.06.014","volume":"46","author":"R Men\u00e9ndez","year":"2010","unstructured":"Men\u00e9ndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodr\u00edguez de Castro F. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2010;46(10):543\u201358.","journal-title":"Arch Bronconeumol"},{"issue":"Suppl 6","key":"8688_CR14","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"17 Suppl 6","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17 Suppl 6(Suppl 6):E1\u201359.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"8688_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/00365548.2012.700120","volume":"44","author":"C Spindler","year":"2012","unstructured":"Spindler C, Str\u00e5lin K, Eriksson L, Hjerdt-Goscinski G, Holmberg H, Lidman C, et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012. Scand J Infect Dis. 2012;44(12):885\u2013902.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"8688_CR16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/crj.12674","volume":"12","author":"B Cao","year":"2018","unstructured":"Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320\u201360.","journal-title":"Clin Respir J"},{"issue":"7 Suppl","key":"8688_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jiac.2015.12.019","volume":"22","author":"K Mikasa","year":"2016","unstructured":"Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, et al. JAID\/JSC guidelines for the treatment of respiratory infectious diseases: the Japanese Association for Infectious Diseases\/Japanese Society of Chemotherapy - the JAID\/JSC guide to clinical management of infectious disease\/guideline-preparing committee respiratory infectious disease WG. J Infect Chemother. 2016;22(7 Suppl):S1\u2013s65.","journal-title":"J Infect Chemother"},{"issue":"2","key":"8688_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3947\/ic.2018.50.2.160","volume":"50","author":"MS Lee","year":"2018","unstructured":"Lee MS, Oh JY, Kang CI, Kim ES, Park S, Rhee CK, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 2018;50(2):160\u201398.","journal-title":"Infect Chemother"},{"issue":"16","key":"8688_CR19","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.162.16.1849","volume":"162","author":"F Arancibia","year":"2002","unstructured":"Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162(16):1849\u201358.","journal-title":"Arch Intern Med"},{"issue":"1","key":"8688_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/resp.12651","volume":"21","author":"ML Metersky","year":"2016","unstructured":"Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology. 2016;21(1):157\u201363.","journal-title":"Respirology"},{"issue":"4","key":"8688_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cir840","volume":"54","author":"S Aliberti","year":"2012","unstructured":"Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54(4):470\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"8688_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/cir813","volume":"54","author":"AF Shorr","year":"2012","unstructured":"Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012;54(2):193\u20138.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"8688_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","volume":"188","author":"Y Shindo","year":"2013","unstructured":"Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8688_CR24","doi-asserted-by":"publisher","first-page":"e0119528","DOI":"10.1371\/journal.pone.0119528","volume":"10","author":"M Falcone","year":"2015","unstructured":"Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One. 2015;10(4):e0119528.","journal-title":"PLoS One"},{"issue":"4","key":"8688_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1086\/422317","volume":"39","author":"AA El Solh","year":"2004","unstructured":"El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis. 2004;39(4):474\u201380.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"8688_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1378\/chest.09-2434","volume":"137","author":"MP Schreiber","year":"2010","unstructured":"Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest. 2010;137(6):1283\u20138.","journal-title":"Chest"},{"issue":"9","key":"8688_CR27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.rmed.2012.04.003","volume":"106","author":"SC Park","year":"2012","unstructured":"Park SC, Kang YA, Park BH, Kim EY, Park MS, Kim YS, et al. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med. 2012;106(9):1311\u20139.","journal-title":"Respir Med"},{"issue":"2","key":"8688_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","volume":"12","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Polverino E, Cill\u00f3niz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153\u201360.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"8688_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/resp.12267","volume":"19","author":"HM Ma","year":"2014","unstructured":"Ma HM, Ip M, Woo J, Hui DS. Development and validation of a clinical risk score for predicting drug-resistant bacterial pneumonia in older Chinese patients. Respirology. 2014;19(4):549\u201355.","journal-title":"Respirology"},{"issue":"1","key":"8688_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12879-017-2788-8","volume":"17","author":"JU Song","year":"2017","unstructured":"Song JU, Park HK, Kang HK, Lee J. Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia. BMC Infect Dis. 2017;17(1):681.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"8688_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/pathogens11030300","volume":"11","author":"FF Tuon","year":"2022","unstructured":"Tuon FF, Dantas LR, Suss PH, TascaRibeiro VS. Pathogenesis of the Pseudomonas aeruginosa biofilm: a review. Pathogens. 2022;11(3):300.","journal-title":"Pathogens"},{"issue":"8","key":"8688_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3201\/eid0908.030054","volume":"9","author":"A Leibovitz","year":"2003","unstructured":"Leibovitz A, Dan M, Zinger J, Carmeli Y, Habot B, Segal R. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg Infect Dis. 2003;9(8):956\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"8688_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","volume":"31","author":"I Quinti","year":"2011","unstructured":"Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315\u201322.","journal-title":"J Clin Immunol"},{"issue":"18","key":"8688_CR34","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs. 2021;81(18):2117\u201331.","journal-title":"Drugs"},{"issue":"5","key":"8688_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17476348.2021.1906225","volume":"15","author":"C Vidaillac","year":"2021","unstructured":"Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649\u201362.","journal-title":"Expert Rev Respir Med"},{"issue":"11","key":"8688_CR36","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","volume":"171","author":"RT Sadikot","year":"2005","unstructured":"Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171(11):1209\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8688_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2017.05.003","volume":"88","author":"P Tofas","year":"2017","unstructured":"Tofas P, Samarkos M, Piperaki ET, Kosmidis C, Triantafyllopoulou ID, Kotsopoulou M, et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. Diagn Microbiol Infect Dis. 2017;88(4):335\u201341.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"8688_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1164\/rccm.200709-1413OC","volume":"177","author":"TF Murphy","year":"2008","unstructured":"Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):853\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"8688_CR39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1086\/593186","volume":"47","author":"L Mart\u00ednez-Solano","year":"2008","unstructured":"Mart\u00ednez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47(12):1526\u201333.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"8688_CR40","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1038\/s41598-022-12904-z","volume":"12","author":"J Poovieng","year":"2022","unstructured":"Poovieng J, Sakboonyarat B, Nasomsong W. Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital. Sci Rep. 2022;12(1):9004.","journal-title":"Sci Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08688-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08688-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08688-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T01:07:16Z","timestamp":1700269636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08688-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8688"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08688-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"5 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research project was approved by the Human Research Ethics Committee of Naresuan University (COA No. 480\/2021) and Buddhachinaraj Hospital (COA No. 112\/2021) on November 22 and December 20, 2021, respectively. All methods were carried out in accordance with relevant guidelines and regulations in the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of the study by Naresuan University Institutional Review Board (NU-IRB) and Buddhachinaraj Phitsanulok Hospital Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"700"}}